| __timestamp | MannKind Corporation | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 18516000 |
| Thursday, January 1, 2015 | 29674000 | 34140000 |
| Friday, January 1, 2016 | 14917000 | 51872000 |
| Sunday, January 1, 2017 | 14118000 | 71772000 |
| Monday, January 1, 2018 | 8737000 | 97501000 |
| Tuesday, January 1, 2019 | 6900000 | 118590000 |
| Wednesday, January 1, 2020 | 6248000 | 169802000 |
| Friday, January 1, 2021 | 12312000 | 192507000 |
| Saturday, January 1, 2022 | 19721000 | 199563000 |
| Sunday, January 1, 2023 | 31283000 | 253598000 |
Infusing magic into the data realm
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, MannKind Corporation and Xencor, Inc. have demonstrated contrasting approaches to R&D investment. MannKind's R&D expenses peaked in 2014, with a significant 41% drop by 2015, reflecting strategic shifts. In contrast, Xencor's R&D spending has shown a consistent upward trajectory, increasing by over 1,200% from 2014 to 2023. This trend underscores Xencor's commitment to expanding its research capabilities and pipeline. By 2023, Xencor's R&D expenses were nearly eight times those of MannKind, highlighting its aggressive investment in innovation. These spending patterns not only reveal each company's strategic priorities but also provide insights into their potential future growth and impact in the biotech sector.
Comparing Innovation Spending: Amgen Inc. and MannKind Corporation
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Xencor, Inc.
R&D Insights: How GSK plc and Xencor, Inc. Allocate Funds
Insmed Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Madrigal Pharmaceuticals, Inc. and Xencor, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
Veracyte, Inc. vs Xencor, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Xencor, Inc.
R&D Insights: How ImmunityBio, Inc. and MannKind Corporation Allocate Funds
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs MannKind Corporation
Who Optimizes SG&A Costs Better? MannKind Corporation or Xencor, Inc.